CN104918952B - 表达屈曲病毒多肽的重组麻疹病毒及其应用 - Google Patents

表达屈曲病毒多肽的重组麻疹病毒及其应用 Download PDF

Info

Publication number
CN104918952B
CN104918952B CN201380055697.6A CN201380055697A CN104918952B CN 104918952 B CN104918952 B CN 104918952B CN 201380055697 A CN201380055697 A CN 201380055697A CN 104918952 B CN104918952 B CN 104918952B
Authority
CN
China
Prior art keywords
chikv
virus
cell
nucleic acid
polynucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380055697.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104918952A (zh
Inventor
F·坦吉
S·布兰德勒
P·德普雷
A·哈贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Themis Bioscience GmbH
Centre National de la Recherche Scientifique
Institut Pasteur
Original Assignee
Themis Bioscience GmbH
Centre National de la Recherche Scientifique
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Themis Bioscience GmbH, Centre National de la Recherche Scientifique, Institut Pasteur filed Critical Themis Bioscience GmbH
Publication of CN104918952A publication Critical patent/CN104918952A/zh
Application granted granted Critical
Publication of CN104918952B publication Critical patent/CN104918952B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18443—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18441—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18444—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380055697.6A 2012-09-27 2013-09-26 表达屈曲病毒多肽的重组麻疹病毒及其应用 Active CN104918952B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306176.4 2012-09-27
EP12306176.4A EP2712871A1 (en) 2012-09-27 2012-09-27 Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
PCT/EP2013/070137 WO2014049094A1 (en) 2012-09-27 2013-09-26 Recombinant measles virus expressing chikungunya virus polypeptides and their applications

Publications (2)

Publication Number Publication Date
CN104918952A CN104918952A (zh) 2015-09-16
CN104918952B true CN104918952B (zh) 2019-01-22

Family

ID=46982495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380055697.6A Active CN104918952B (zh) 2012-09-27 2013-09-26 表达屈曲病毒多肽的重组麻疹病毒及其应用

Country Status (16)

Country Link
US (1) US9655961B2 (cg-RX-API-DMAC10.html)
EP (2) EP2712871A1 (cg-RX-API-DMAC10.html)
JP (1) JP6251273B2 (cg-RX-API-DMAC10.html)
KR (1) KR102077131B1 (cg-RX-API-DMAC10.html)
CN (1) CN104918952B (cg-RX-API-DMAC10.html)
AU (1) AU2013322635C1 (cg-RX-API-DMAC10.html)
BR (1) BR112015006763B1 (cg-RX-API-DMAC10.html)
CA (1) CA2884585C (cg-RX-API-DMAC10.html)
DK (1) DK2900687T3 (cg-RX-API-DMAC10.html)
ES (1) ES2682268T3 (cg-RX-API-DMAC10.html)
IN (1) IN2015DN02546A (cg-RX-API-DMAC10.html)
MX (1) MX359981B (cg-RX-API-DMAC10.html)
PH (1) PH12015500499A1 (cg-RX-API-DMAC10.html)
PT (1) PT2900687T (cg-RX-API-DMAC10.html)
SG (1) SG11201502411PA (cg-RX-API-DMAC10.html)
WO (1) WO2014049094A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI111811B (fi) * 1998-06-05 2003-09-30 Outokumpu Oy Menetelmä kuivauksen tehostamiseksi
WO2016122414A1 (en) * 2015-01-29 2016-08-04 Agency For Science, Technology And Research Nanocapsules carrying chikungunya-associated peptides
WO2017060360A1 (en) * 2015-10-06 2017-04-13 Invectys Polyepitope constructs for use in immunotherapy
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
WO2017221076A1 (en) 2016-06-24 2017-12-28 Institut Pasteur Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases
CA3030451C (en) * 2016-07-15 2023-09-05 Etubics Corporation Compositions and methods for alphavirus vaccination
KR101919403B1 (ko) * 2016-11-04 2018-11-16 연세대학교 원주산학협력단 재조합 단백질 및 그의 용도
EP3412307A1 (en) * 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
CN118662621A (zh) * 2017-09-21 2024-09-20 瓦尔尼瓦公司 包含免疫原性屈公病毒chikv-delta5nsp3的医药组成物的制备方法
MX2020004833A (es) 2017-11-09 2021-01-08 Pasteur Institut Un poliepitopo quimerico del virus del zika que comprende proteinas no estructurales y su uso en una composicion inmunogenica.
WO2019156223A1 (ja) * 2018-02-09 2019-08-15 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
EP3581646A1 (en) 2018-06-15 2019-12-18 Themis Bioscience GmbH Integrated manufacturing and chromatographic system for virus production
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
CN115433741A (zh) * 2022-06-23 2022-12-06 广西大学 盖他病毒为载体表达报告蛋白的重组病毒的构建方法
CN117904059A (zh) * 2022-10-17 2024-04-19 清华大学 一种基于麻疹病毒载体包装病毒样颗粒冠状病毒疫苗的方法
KR102864666B1 (ko) * 2025-04-21 2025-09-29 대한민국 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1375512B1 (en) 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
CA2545597A1 (en) 2006-03-15 2007-09-15 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
DK1939214T3 (da) 2006-12-22 2013-10-14 Pasteur Institut Celler og metodik til at generere ikke-segmenterede negativstrengede RNA-vira
EP2274442B1 (en) * 2008-04-04 2016-06-29 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
WO2011082388A2 (en) 2009-12-31 2011-07-07 Medigen, Inc . Infectious dna vaccines against chikungunya virus
WO2012106356A2 (en) * 2011-01-31 2012-08-09 GOVERNMENT OF THE USA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Virus-like particles and methods of use
CN102321639B (zh) * 2011-09-08 2013-06-26 中国疾病预防控制中心病毒病预防控制所 基孔肯雅病毒病毒样颗粒的制备方法和应用
MX357202B (es) * 2012-02-16 2018-06-28 Vlp Therapeutics Llc Composicion de particula tipo virus.
US8961995B2 (en) * 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317308A (zh) * 2008-11-26 2012-01-11 美国国有健康与人类服务部 类病毒组合物颗粒及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses;Samantha Brandler等;《Vaccine》;20100924;第28卷(第41期);第6730、6733页 *
Recombinant vector derived from live attenuated measles virus: Potential for flavivirus vaccines;Samantha Brandler，et al.;《Comparative Immunology, Microbiology & Infectious Diseases》;20070914;第31卷(第2-3期);第271-281页 *

Also Published As

Publication number Publication date
EP2900687B1 (en) 2018-05-02
BR112015006763B1 (pt) 2023-10-24
US20150238592A1 (en) 2015-08-27
MX359981B (es) 2018-10-18
DK2900687T3 (en) 2018-08-06
AU2013322635B2 (en) 2017-10-12
EP2712871A1 (en) 2014-04-02
SG11201502411PA (en) 2015-04-29
MX2015003717A (es) 2015-10-22
ES2682268T3 (es) 2018-09-19
PT2900687T (pt) 2018-08-06
CA2884585C (en) 2021-12-14
HK1211951A1 (en) 2016-06-03
AU2013322635A1 (en) 2015-04-02
PH12015500499B1 (en) 2015-04-27
AU2013322635C1 (en) 2018-02-08
JP2015532090A (ja) 2015-11-09
US9655961B2 (en) 2017-05-23
IN2015DN02546A (cg-RX-API-DMAC10.html) 2015-09-11
JP6251273B2 (ja) 2017-12-20
WO2014049094A1 (en) 2014-04-03
KR20150058506A (ko) 2015-05-28
PH12015500499A1 (en) 2015-04-27
EP2900687A1 (en) 2015-08-05
KR102077131B1 (ko) 2020-04-09
CA2884585A1 (en) 2014-04-03
BR112015006763A2 (pt) 2019-09-03
CN104918952A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
US9655961B2 (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications
US10227385B2 (en) Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection
CN105420261B (zh) 一种新城疫病毒耐热改造方法及应用
CN103266091B (zh) A型口蹄疫重组疫苗株及其制备方法和应用
BRPI0312173B1 (pt) Vetor e processo para a preparação de partículas infecciosas de vírus do sarampo
CN110218706B (zh) 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用
EP3634482A1 (en) Recombinant measles virus expressing zika virus proteins and their applications
CN109321534A (zh) 一种重组基因viii型新城疫病毒弱毒株
CN111961654B (zh) 耐热表型稳定遗传、携带负标记的重组口蹄疫病毒无毒株及o/a型口蹄疫二价灭活疫苗
CN103160473B (zh) 用于拯救麻疹病毒的组合物、试剂盒、用途及方法
CN111996201B (zh) 一种重组a型口蹄疫病毒vp1基因的塞内卡重组病毒、重组疫苗株及其制备方法和应用
CN113416714A (zh) 一种表达埃博拉gp蛋白的重组病毒及其制备方法和应用
CN109136200A (zh) 一种重组传染性造血器官坏死病毒及其构建方法与应用
CN109957550A (zh) 流感病毒的拯救方法及其组合物
CN111996202B (zh) 一种重组o型口蹄疫病毒vp1基因的塞内卡重组病毒、重组疫苗株及其制备方法和应用
CN106520789B (zh) 一种dna分子与重组病毒及它们的制备方法和用途
CN116144612A (zh) 重组乙型流感病毒及其制备方法与应用
CN115820572A (zh) 一种表达双拷贝拉沙热病毒gp基因的重组病毒株及其构建方法和应用
CN110042084A (zh) 一种活病毒流感疫苗的生产方法以及制剂
CN118561969B (zh) 一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗
CN118853589B (zh) 一种黄热病毒疫苗株3’utr缺失突变体的拯救及在制备减毒活疫苗中的应用
HK1211951B (en) Recombinant measles virus expressing chikungunya virus polypeptides and their applications

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211951

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant